Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kreutzer, Jan N ^a   Ruzzene, Maria ^b   Guerra, Barbara ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CASEIN KINASE IIALPHA; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MESSENGER RNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PANCREAS CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 77955666237     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-440     Document Type: Article

References (38)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2(12):897-909. 10.1038/nrc949, 12459728.
2. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 2009, 9(10):1487-97. 10.1586/era.09.107, 19828010.
3. Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs 2009, 14(2):311-28. 10.1517/14728210902972502, 19466902.
4. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249. 10.1101/gad.1415606, 16702400.
5. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat 2009, 6:412-422.
6. Guerra B, Issinger OG. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 1999, 20(2):391-408. 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N, 10197447.
7. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2?. FASEB J 2003, 17(3):349-68. 10.1096/fj.02-0473rev, 12631575.
8. Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008, 15(19):1870-86. 10.2174/092986708785132933, 18691045.
9. Bibby AC, Litchfield DW. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci 2005, 1(2):67-79. 1142214, 15951851.
10. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 2008, 28:131-139. 10.1128/MCB.01119-07, 2223292, 17954558.
11. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, Cochet C, Issinger OG, Boldyreff B. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003, 23:908-915. 10.1128/MCB.23.3.908-915.2003, 140710, 12529396.
12. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. Nat Genet 1999, 23:118-121. 10.1038/12729, 10471512.
13. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008, 1784(1):33-47.
14. Giroux V, Iovanna J, Dagorn JC. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 2006, 20(12):1982-91. 10.1096/fj.06-6239com, 17012250.
15. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, Ruzzene M. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007, 26(48):6915-26. 10.1038/sj.onc.1210495, 17486073.
16. Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 2008, 27(37):4986-97. 10.1038/onc.2008.146, 18469858.
17. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005, 12(6):668-77. 10.1038/sj.cdd.4401604, 15818404.
18. Guerra B, Siemer S, Boldyreff B, Issinger OG. Protein kinase CK2: evidence for a protein kinase CK2beta subunit fraction, devoid of the catalytic CK2alpha subunit, in mouse brain and testicles. FEBS Lett 1999, 462(3):353-7. 10.1016/S0014-5793(99)01553-7, 10622724.
19. Rosenberg L. Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine. Int J Pancreatol 1997, 22(2):81-93.
20. Pham NA, Tsao MS, Cao P, Hedley DW. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas 2007, 35(3):16-26. 10.1097/mpa.0b013e318095a747, 17575540.
21. Zhang C, Vilk G, Canton DA, Litchfield DW. Phosphorylation regulates the stability of the regulatory CK2beta subunit. Oncogene 2002, 21(23):3754-64. 10.1038/sj.onc.1205467, 12032843.
22. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003, 369:1-15. 10.1042/BJ20021469, 1223072, 12396231.
23. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76(6):1025-37. 10.1016/0092-8674(94)90380-8, 8137421.
24. Kallunki T, Su B, Tsigelny I, Sluss HK, Dérijard B, Moore G, Davis R, Karin M. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 1994, 8(24):2996-3007. 10.1101/gad.8.24.2996, 8001819.
25. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001, 98(24):1-61368. 33345, 11136239.
26. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005, 11(8):353-61. 10.1016/j.molmed.2005.06.007, 16002336.
27. Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci 2009, 66(20):3363-73. 10.1007/s00018-009-0108-1, 19662498.
28. Niefind K, Issinger OG. Primary and secondary interactions between CK2alpha and CK2beta lead to ring-like structures in the crystals of the CK2 holoenzyme. Mol Cell Biochem 2005, 274(1-2):3-14. 10.1007/s11010-005-3114-0, 16335523.
29. Olsen BB, Boldyreff B, Niefind K, Issinger OG. Purification and characterization of the CK2alpha'-based holoenzyme, an isozyme of CK2alpha: a comparative analysis. Protein Expr Purif 2006, 47(2):651-61. 10.1016/j.pep.2005.12.001, 16442308.
30. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270(5240):1326-31. 10.1126/science.270.5240.1326, 7481820.
31. Brantley-Finley C, Lyle CS, Du L, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP, Chambers TC. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 2003, 66(3):459-69. 10.1016/S0006-2952(03)00255-7, 12907245.
32. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996, 93(8):3636-41. 10.1073/pnas.93.8.3636, 39663, 8622988.
33. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998, 21(2):81-6. 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R, 9496907.
34. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999, 59(15):3581-7.
35. Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res 2001, 97(2):123-30. 10.1006/jsre.2001.6145, 11341787.
36. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000, 103(2):253-62. 10.1016/S0092-8674(00)00117-3, 11057898.
37. Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, Kono A, Egawa S, Yamaguchi K, Hayashizaki Y, Sekiya T. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996, 225(3):968-74. 10.1006/bbrc.1996.1280, 8780719.
38. Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Onc Rep 2007, 18:695-701.